相关实验视频

Updated: Jul 3, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

在非小细胞肺癌中准MEK

Matthew S Lara¹, Collin M Blakely², Jonathan W Riess¹

¹University of California Davis Comprehensive Cancer Center and the UC Davis School of Medicine, Sacramento CA, USA.

Current problems in cancer

|February 10, 2024

概括

中原激活蛋白激酶 (MAPK) 途径抑制剂在与其他疗法相结合时,在非小细胞肺癌 (NSCLC) 中表现有前途. 包括BRAF抑制剂在内的组合策略正在探索,以改善瘤驱动NSCLC中的抗瘤活性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

线原激活蛋白激酶 (MAPK) 途径,特别是MEK,调节非小细胞肺癌 (NSCLC) 的瘤细胞存活率和增殖.
激活MEK突变在NSCLC中罕见;然而,通路激活通常是由上游致癌突变驱动的.
单独使用MEK抑制剂的疗法在NSCLC中表现出有限的疗效.

研究的目的:

审查目前NSCLC中MEK抑制剂治疗策略.
为了突出正在进行的临床试验,调查MEK抑制剂组合.
为未来的癌基因驱动NSCLC合理组合疗法提供信息.

主要方法:

关于NSCLC中MEK抑制剂策略的最新数据的文献综述.
早期临床试验发现的总结.
分析涉及MEK抑制剂的组合疗法.

主要成果:

与BRAF抑制相结合的MEK抑制在BRAF V600突变NSCLC中显示出显著的抗瘤活性.
涉及MEK抑制剂的组合疗法在癌基因驱动的NSCLC中显示出令人鼓舞的结果.
目前正在进行的试验正在探索与免疫疗法,化疗和其他向药物的组合.

结论:

MEK 抑制剂是NSCLC的一个有希望的治疗点,特别是在组合治疗方案中.
结合策略对于克服MEK抑制剂单一治疗的局限性至关重要.
未来的研究应该专注于在癌基因驱动的NSCLC中抑制MEK-ERK通路的合理组合.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...